Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Juvenile Macular Degeneration Treatment Market?

In recent times, there has been a notable expansion in the market size of the treatment for juvenile macular degeneration. It is projected to escalate from $1.28 billion in 2024 to $1.39 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.2%. This growth during the historic period is a consequence of increasing instances of genetic eye disorders, heightened investments in ophthalmic research, a greater emphasis on children’s eye health, a surge in vision impairment cases among children, and the rising adoption of artificial intelligence in eye care diagnostics.

What Growth Rate Is Forecasted for the Juvenile Macular Degeneration Treatment Market by 2029?

The market for juvenile macular degeneration treatments is projected to witness significant expansion in the coming years, with a predicted rise to $1.88 billion in 2029 and a compound annual growth rate (CAGR) of 8.0%. This anticipated growth over the forecasting period can be credited to various factors such as an increasing geriatric population, a surge in startups dedicated to ophthalmic biotechnology, greater emphasis on targeted drug delivery systems, a heightened number of clinical trials, and rising investments in gene therapy. Expected trends within this forecast period encompass advancements in genetic testing, growth in gene therapy developments, stem cell research, regulatory backing for novel therapies, and personalized medicinal practices.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23433&type=smp

Which Key Companies Are Shaping the Future of the Juvenile Macular Degeneration Treatment Market?

Major companies operating in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, Kubota Pharmaceutical Holdings Co. Ltd.

Which Factors Are Driving Demand in the Juvenile Macular Degeneration Treatment Industry?

The escalating incidence of retinal issues is predicted to spur the expansion of the juvenile macular degeneration treatment market in the future. Retinal issues encompass a range of conditions that impact the retina, which is the area at the rear of the eye that is sensitive to light and can cause vision disruption or loss. The upsurge in retinal disorders is linked to the growing frequency of diabetes, which can contribute to problems like diabetic retinopathy that progressively harms the retina. Juvenile macular degeneration therapies play a vital role in managing retinal disorders in younger patients by helping maintain vision through early intervention. For example, Retina Australia, a non-profit organization based in Australia, released a report in November 2024 stating that approximately 19,000 individuals or around 1 in 1,380 people in Australia are believed to be living with an inherited retinal disease (IRD). Moreover, based on the statistics from the National Eye Institute, a health institute based in the US, it is projected that the number of Americans suffering from advanced age-related macular degeneration (AMD) will rise from the present 2.1 million to about 3.7 million by 2030. Hence, the climbing occurrence of retinal issues is fueling the expansion of the juvenile macular degeneration treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23433&type=smp

How Is the Juvenile Macular Degeneration Treatment Market Segmented by Several Divisions?

The juvenile macular degeneration treatment market covered in this report is segmented –

1) By Type: Wet Age-Related Macular Degeneration, Dry Age-Related Macular Degeneration

2) By Treatment: Devices, Drugs, Surgery

3) By Application: Vision Preservation, Disease Management, Symptom Relief, Preventive Care, Clinical Trials

4) By Sales Channel: Hospitals, Ambulatory Surgical Centres, Other Sales Channel

Subsegments:

1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy, Photodynamic Therapy (PDT), Laser Therapy

2) By Dry Age-Related Macular Degeneration: Nutritional Supplements, Gene Therapy, Stem Cell Therapy

What are the Emerging Market Trends Driving the Growth of the Juvenile Macular Degeneration Treatment Industry?

Leading firms in the juvenile macular degeneration treatment marketplace are concentrating on creating novel solutions like dual adeno-associated viral (AAV) vectors. This will bolster gene therapy delivery and enhance therapeutic efficacy for those afflicted with juvenile macular degeneration. Dual AAV vectors are a gene therapy methodology that utilizes two AAV vectors to carry large curative genes, which single AAV cannot package. For instance, in March 2025, the pioneering patient dosing in SpliceBio’s Phase 1/2 ASTRA study was declared. SpliceBio is a Spain-based biotechnology business and they’ve developed a dual AAV vector gene therapy named SB-007. Its purpose is to rejuvenate the full-length ABCA4 protein expression. The therapy’s goal is to cater to a potential cure for juvenile macular degeneration (or Stargardt disease), a congenital retinal disorder with no sanctioned treatments, intending to benefit all patients irrespective of their genetic variations. This achievement signifies a substantial stride towards the evolution of efficient gene treatments for infrequent retinal diseases.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/juvenile-macular-degeneration-treatment-global-market-report

Which Regions Are Driving Growth in the Juvenile Macular Degeneration Treatment Market?

North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23433

This Report Delivers Insight On:

1. How big is the juvenile macular degeneration treatment market, and how is it changing globally?

2. Who are the major companies in the juvenile macular degeneration treatment market, and how are they performing?

3. What are the key opportunities and risks in the juvenile macular degeneration treatment market right now?

4. Which products or customer segments are growing the most in the juvenile macular degeneration treatment market?

5. What factors are helping or slowing down the growth of the juvenile macular degeneration treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model